There are currently 49 active clinical trials seeking participants for NSCLC research studies. The states with the highest number of trials for Autism participants are California, New York, Florida and Texas.
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
NCT04746924
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Alaska Oncologyand Hematology, Llc, Anchorage, Alaska +102 locations
Conditions: Non-small Cell Lung Cancer, NSCLC
Register for Updates
A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer
NCT06246110
Recruiting
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Medstar Franklin Square Cancer Center at Loch Raven Campus, Baltimore, Maryland +1 locations
Conditions: NSCLC
Register for Updates
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835
Recruiting
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the RP2D of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer. The study will furth... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: UCSD, La Jolla, California +38 locations
Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study to Investigate LYL797 in Adults With Solid Tumors
NCT05274451
Recruiting
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC and NSCLC patients. The second part of the study will test that dose in additional TNBC and NSCLC patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: Mayo Clinic, Scottsdale, Arizona +17 locations
Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC
Register for Updates
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors
NCT05668585
Recruiting
The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: Florida Cancer Specialists, Sarasota, Florida +14 locations
Conditions: Solid Tumors, Melanoma, NSCLC, CRC, ATC
Register for Updates
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
NCT05798663
Recruiting
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Missouri Baptist Medical Center, Saint Louis, Missouri +3 locations
Conditions: NSCLC
Register for Updates
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
NCT05332925
Recruiting
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
Gender:
All
Ages:
Between 18 years and 110 years
Trial Updated:
02/21/2024
Locations: The University of Kansas Cancer Center (KUCC), Fairway, Kansas +1 locations
Conditions: Lung Cancer, NSCLC, NSCLC Stage IV
Register for Updates
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
NCT04114136
Recruiting
Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which current standard of care treatment for their stage of disease would be with Pembrolizumab or Nivolumab monotherapy, who meet eligibility criteria will undergo a biopsy (core or excisional/incisional; FNA not adequate) for baseline tissue. Patients will then be randomi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
Register for Updates
Epidemiology of Young Lung Cancer - Survey
NCT04640259
Recruiting
This is a 100% virtual (remote), case-case study to explore potential environmental, lifestyle and genetic factors that may be associated with driver mutations of young lung cancer in the U.S.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: USC Keck School of Medicine, Los Angeles, California +1 locations
Conditions: NSCLC
Register for Updates
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
NCT05631574
Recruiting
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Cancer Treatment Centers of America - Phoenix, Goodyear, Arizona +22 locations
Conditions: Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
Register for Updates
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT05259696
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: UC San Diego Moores Cancer Center, La Jolla, California +12 locations
Conditions: Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
Register for Updates
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
NCT02279004
Recruiting
Tumor genotyping has become an essential biomarker for the care of advanced lung cancer and melanoma, and is currently used to identify patients for treatment with targeted kinase inhibitors like erlotinib and vemurafenib. However, tumor genotyping can be slow and cumbersome, and is limited by availability of tumor biopsy tissue for testing. The aim of this study is to prospectively evaluate a blood-based genotyping tool that can quantify the presence of oncogenic mutations (EGFR, KRAS, BRAF) in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: NSCLC, Melanoma
Register for Updates